← Back to Research Radar
Academic Publication Academic Publication

Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances

63
Citations
March 21, 2025
Published Date

Research Abstract & Technology Focus

Peptide and protein (PP) therapeutics are highly specific and potent biomolecules that treat chronic and complex diseases. However, their oral delivery is significantly hindered by enzymatic degradation, instability, and poor permeability through the gastrointestinal (GI) epithelium, resulting in low bioavailability. Various strategies have emerged as transformative solutions to address existing challenges, offering enhanced protection, stabilization, and absorption of PPs. These strategies primarily focus on two major challenges: protecting the PP against harsh conditions and enhancing permeation across the intestinal membrane. Innovative approaches such as pH modulation and incorporation of enzyme inhibitors are usually used to mitigate proteolytic degradation of PP during transit across the GI tract. In a similar vein, absorption enhancers and prodrug strategies facilitate epithelial transport, while targeted delivery systems focus on specific areas of the GI tract to enhance absorption. Likewise, mucus-penetrating and mucoadhesive strategies have enhanced retention and interaction with epithelial cells, effectively overcoming barriers like the mucus layer and tight epithelial junctions. Furthermore, structural modifications such as lipidation, peptide cyclization, and polyethylene glycosylation are promising alternatives to render stability, prolong circulation time, and membrane permeability. In particular, functional biomaterials, active targeting, and lymphatic transport strategies have provided new platforms for oral PP delivery. Advancing in materials science, nanotechnology, and the disruption of medical devices holds new frontiers to overcome barriers. Despite substantial advancements, the limited success in clinical translation underscores the urgency of innovative strategies. This review presents oral PPs as a promising platform, highlighting the key barriers and strategies to transform their therapeutic landscapes.
Read Full Literature

Correlated Market Trend: Delivery Driver

Bridging academia to market: The 60-day public search velocity mapping directly to the core technology of this paper. Dashed line represents 7-day moving average.

AI Semantic Synergy Context

Connecting this academic literature to real-world market discussions and products.

crossref.org › academic paper
0%

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

AbstractThe glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell ty...

roipad.com › trend story
0%

Modulating nuclear stiffness and envelope barrier facilitates AAV nuclear entry and reduces immunogenicity

Low efficiency and immunotoxicity limit rAAVs clinical use. Here, the authors show that encapsulating rapamycin in PF127 micelles modulates cellular biomechanics, enhancing AAV-mediated gene transf...

crossref.org › academic paper
0%

Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides

Abstract With their diverse biological activities, peptides are promising candidates for therapeutic applications, showing antimicrobial, antitumour and hormonal signalling capabilit...

crossref.org › academic paper
0%

Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles

Biological variability poses significant challenges in the development of effective therapeutics, particularly when it comes to drug solubility and bioavailability. Poor solubility across varying p...

crossref.org › academic paper
0%

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

PURPOSE To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti–human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristati...

Frequently Asked Questions (FAQ)

Curated market intelligence mapped to this research.

What is the core focus of the research titled 'Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances'?

This literature focuses on: Peptide and protein (PP) therapeutics are highly specific and potent biomolecules that treat chronic and complex diseases. However, their oral delivery is significantly hindered by enzymatic degradation, instability, and poor permeability through ...

What other academic literature is closely related to 'Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances'?

Yes, highly correlated activity was mapped. An entry titled 'Glucagon-like peptide-1 receptor: mechanisms and advances in therapy' discusses this: AbstractThe glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is ...

Are there commercial applications of 'Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances' in market news publications?

Yes, highly correlated activity was mapped. An entry titled 'Modulating nuclear stiffness and envelope barrier facilitates AAV nuclear entry and reduces immunogenicity' discusses this: Low efficiency and immunotoxicity limit rAAVs clinical use. Here, the authors show that encapsulating rapamycin in PF127 micelles modulates cellula...

Cite this Market Intelligence Report

Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.